Oral Therapies for Multiple Sclerosis: A Review of Agents in Phase III Development or Recently Approved

ISSN： 1172-7047

Source： CNS Drugs, Vol.25, Iss.1, 2011-01, pp. : 37-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral Agents in Multiple Sclerosis

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 14, Iss. 1, 2015-03 ,pp. : 15-25

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging therapies in multiple sclerosis

By Farrell Rachel Heaney Dominic Giovannoni Gavin

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 4, 2005-11 ,pp. : 797-816

Informa Healthcare

Access to resources Recommend Favorite

A Review of: “HPCL Methods for Recently Approved Pharmaceuticals”

By Williams Robert

Drug Development and Industrial Pharmacy, Vol. 32, Iss. 7, 2006-08 ,pp. : 907-907

Informa Healthcare

Access to resources Recommend Favorite

Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 8, Iss. 6, 2009-12 ,pp. : 512-519

Bentham Science Publishers

Access to resources Recommend Favorite

US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis: Review of Adverse Effect Profiles

By Steven L. Galetta Clyde Markowitz

CNS Drugs, Vol. 19, Iss. 3, 2005-01 ,pp. : 239-252

Adis International

Access to resources Recommend Favorite